MOTS-c (mitochondrial-derived peptide)
Also referred to as MOTS-c peptide, mitochondrial-derived peptide MOTS-c.
Status: Investigational. MOTS-c is not an FDA-approved drug product. It is not listed in DailyMed and has no approved indication. It circulates in research and grey-market contexts as a laboratory reagent, not as a medicine with an established safety or efficacy record in people.
MOTS-c is a short peptide encoded within the mitochondrial genome that has drawn research interest as a signal linking mitochondrial function to whole-body metabolism. Almost everything known about it comes from mouse and cell-culture experiments rather than from people. It is not an approved drug, and no clinical trial has established what it does when given to humans. Claims about fat loss or longevity benefit in people are not supported by the current published record.
What it is
MOTS-c is a 16-amino-acid peptide translated from a short open reading frame inside the mitochondrial 12S rRNA gene, distinct from peptides encoded by nuclear DNA. It was first described in 2015 as one of several 'mitochondrial-derived peptides' that appear to act as signals between mitochondria and the rest of the cell. Material sold as MOTS-c outside of a research setting is an unregulated synthetic peptide, not a pharmaceutical product.
Why people ask about it
Patients encounter MOTS-c through longevity and biohacking communities that cite its mitochondrial origin as evidence it might influence metabolic aging, exercise capacity, or insulin sensitivity. The framing often gets ahead of the underlying science, which is still confined to laboratory models. People reasonably want to know whether the animal findings say anything about a human dose that does not exist in any approved form.
Proposed mechanism
In mouse and cell studies, MOTS-c is proposed to translocate to the nucleus under metabolic stress and influence gene expression tied to energy metabolism, partly through AMPK-related signalling. It has also been described as modulating glucose uptake in skeletal muscle tissue in rodent experiments. These are laboratory-derived hypotheses about mechanism, not demonstrated effects in humans, and the translational distance between a mouse muscle assay and a person's metabolism is substantial and unresolved.
What researchers have studied
- Effects on glucose uptake and insulin sensitivity in rodent models
- Exercise capacity and muscle metabolism in mice
- Age-related changes in circulating MOTS-c levels in observational human cohorts
- AMPK pathway activation in cultured cells
- Diet-induced obesity models in mice
- Basic characterization of mitochondrial-derived peptide biology
Human evidence
- No published randomized controlled trials of administered MOTS-c in humans were identified.
- Existing human data are limited to observational correlations between endogenous circulating MOTS-c levels and age or fitness, which cannot establish that giving the peptide would do anything.
- There is no established human pharmacokinetic profile, so basic questions about absorption, half-life, or exposure in people remain unanswered.
- Because there is no human trial, there is no human safety database of any size to draw on.
Preclinical evidence
- Mouse studies report improved glucose tolerance and reduced diet-induced obesity with administered MOTS-c (animal work).
- Cell-culture experiments describe AMPK activation and altered gene expression under MOTS-c exposure (cell work).
- Rodent exercise studies associate MOTS-c with changes in skeletal muscle metabolic markers (animal work).
- Observational studies in mice link MOTS-c decline to aging phenotypes, though this is correlational (animal work).
What is not yet known
- Whether any effect seen in mice translates to a comparable effect in humans.
- What a physiologically relevant human exposure would even look like, since no human pharmacokinetic study exists.
- Long-term safety of repeated exposure in people, including effects on cell growth signalling.
- Whether product sold as MOTS-c outside a laboratory setting is pure, correctly identified, or sterile.
- How MOTS-c would interact with existing metabolic or endocrine conditions or medications.
- Whether any benefit described in rodents would be detectable, meaningful, or durable in a person.
Regulatory status and access
Compounding is never approval, and MOTS-c is not a substance GOAL.MD compounds, dispenses, or recommends for use outside of research. Ask about current availability. Only a physician can determine whether any discussion of this ingredient is medically appropriate, and that determination happens after an individualized evaluation.
Known and potential risks
- No human safety data exist, so unknown or unrecognized risks cannot be ruled out.
- Material obtained outside a regulated pharmaceutical supply chain carries risk of contamination, incorrect concentration, or misidentification.
- Because MOTS-c intersects with growth and metabolic signalling pathways in animal models, unknown effects on cell proliferation cannot be excluded without human study.
- Self-directed use without physician oversight removes the ability to monitor for adverse effects.
- Interactions with diabetes medications or other metabolic therapies have not been studied.
- Legal and quality status of purchased peptide material varies and is not verified by any standard patients can check themselves.
Cautions and who may not be a candidate
- Pregnancy and breastfeeding, given the complete absence of human safety data.
- Any personal or strong family history of malignancy, given unresolved questions about growth signalling pathways in preclinical work.
- Undiagnosed metabolic or endocrine symptoms, which warrant standard diagnostic evaluation rather than an unproven research peptide.
- Use alongside insulin or other glucose-lowering medications without physician supervision.
- Known allergy or prior adverse reaction to synthetic peptide products.
- Any expectation that this substance is a substitute for established metabolic care.
Questions to discuss with a physician
- What does the absence of human trial data mean for assessing safety in my specific case?
- Are there approved, evidence-based options that address the metabolic goal I'm asking about?
- How would you monitor for adverse effects if this were ever discussed as part of a research context?
- What is known about how MOTS-c might interact with medications I currently take?
- How do you evaluate the quality or sourcing of a research peptide?
- What would meaningful evidence of benefit in humans actually need to look like?
Frequently asked questions
Is MOTS-c FDA-approved?
No. MOTS-c is not an FDA-approved drug product and has no approved indication. It is an investigational peptide studied almost exclusively in laboratory and animal research.
Does GOAL.MD sell or prescribe MOTS-c?
This page is educational. It describes the current state of published research and does not represent an offer, prescription, or sale of MOTS-c.
Has MOTS-c been tested in humans?
No published controlled human trials of administered MOTS-c were identified. Human data are limited to observational studies of naturally circulating MOTS-c levels, which is a different question from what happens when it is given as a substance.
Can MOTS-c help with weight loss?
There is no human evidence to support that claim. Effects on body weight and glucose metabolism have been described only in mouse studies, and it is not known whether they apply to people.
Where does MOTS-c come from?
It is a short peptide encoded by mitochondrial DNA, first described in scientific literature in 2015 as part of a family of mitochondrial-derived peptides.
Is MOTS-c the same as growth hormone peptides like ipamorelin?
No. MOTS-c is proposed to act on metabolic and mitochondrial signalling pathways, a different mechanism than growth hormone secretagogues, and the two are studied for different reasons.
Is it safe to buy MOTS-c online?
Products sold outside a regulated pharmaceutical supply chain are not verified for purity, concentration, or sterility, and there is no human safety database to reference if something goes wrong.
What would need to happen before MOTS-c could be considered evidence-based?
Controlled human trials establishing safety, appropriate exposure, and measurable benefit would be needed. None have been published to date.
Does aging reduce MOTS-c levels naturally?
Some observational studies report lower circulating MOTS-c with age, but this is a correlation, not proof that restoring levels would produce any benefit.
Who should I talk to before considering any investigational peptide?
A licensed physician who can review your health history and explain what is and is not known, since only a physician can determine what is appropriate for you after an individualized evaluation.
What is MOTS-c?
MOTS-c is a 16-amino-acid peptide translated from a short open reading frame inside the mitochondrial 12S rRNA gene, distinct from peptides encoded by nuclear DNA. It was first described in 2015 as one of several 'mitochondrial-derived peptides' that appear to act as signals between mitochondria and the rest of the cell. Material sold as MOTS-c outside of a research setting is an unregulated synthetic peptide, not a pharmaceutical product.
Does the legal or regulatory status of MOTS-c tell me whether it works?
No. Regulatory status describes what may lawfully be made, prescribed, or sold, and it is a separate question from what the research shows. On this page the regulatory description and the evidence tiers are kept apart so neither is mistaken for the other.
Can a licensed U.S. compounding pharmacy prepare MOTS-c?
Compounding is never approval, and MOTS-c is not a substance GOAL. MD compounds, dispenses, or recommends for use outside of research.
What human evidence exists for MOTS-c?
No published controlled human trials were identified for the uses discussed here. No published randomized controlled trials of administered MOTS-c in humans were identified.
Have there been controlled human trials of MOTS-c?
No adequately controlled human trial for the uses discussed here was identified. Anything presented elsewhere as a human result is an extrapolation from laboratory or animal work, or an anecdote.
What have animal and laboratory studies of MOTS-c reported?
Mouse studies report improved glucose tolerance and reduced diet-induced obesity with administered MOTS-c (animal work); Cell-culture experiments describe AMPK activation and altered gene expression under MOTS-c exposure (cell work); Rodent exercise studies associate MOTS-c with changes in skeletal muscle metabolic markers (animal work). These are animal, tissue, or cell-culture findings. They describe a model, not a demonstrated result in people.
Do the animal findings for MOTS-c mean it works in people?
No. Findings in animals or in cell culture routinely fail to reproduce in humans, and a positive laboratory model is not evidence of a human benefit. Whether any of this translates to people is exactly what has not been established.
How is MOTS-c proposed to work?
In mouse and cell studies, MOTS-c is proposed to translocate to the nucleus under metabolic stress and influence gene expression tied to energy metabolism, partly through AMPK-related signalling. It has also been described as modulating glucose uptake in skeletal muscle tissue in rodent experiments. This is a proposed pathway rather than a demonstrated effect.
What is MOTS-c being studied for?
Published work has focused on Effects on glucose uptake and insulin sensitivity in rodent models; Exercise capacity and muscle metabolism in mice; Age-related changes in circulating MOTS-c levels in observational human cohorts; AMPK pathway activation in cultured cells. A research focus describes where questions are being asked, not where answers have been found.
What is still unknown about MOTS-c?
Whether any effect seen in mice translates to a comparable effect in humans; What a physiologically relevant human exposure would even look like, since no human pharmacokinetic study exists; Long-term safety of repeated exposure in people, including effects on cell growth signalling; Whether product sold as MOTS-c outside a laboratory setting is pure, correctly identified, or sterile.
What are the risks of MOTS-c?
No human safety data exist, so unknown or unrecognized risks cannot be ruled out; Material obtained outside a regulated pharmaceutical supply chain carries risk of contamination, incorrect concentration, or misidentification; Because MOTS-c intersects with growth and metabolic signalling pathways in animal models, unknown effects on cell proliferation cannot be excluded without human study.
Who should not consider MOTS-c?
A physician would generally consider it inappropriate in these situations without specialist input: Pregnancy and breastfeeding, given the complete absence of human safety data; Any personal or strong family history of malignancy, given unresolved questions about growth signalling pathways in preclinical work; Undiagnosed metabolic or endocrine symptoms, which warrant standard diagnostic evaluation rather than an unproven research peptide; Use alongside insulin or other glucose-lowering medications without physician supervision.
Is MOTS-c appropriate during pregnancy or breastfeeding?
No. Pregnancy and breastfeeding are listed as situations where this is not appropriate, because the safety data needed to make that judgement in those populations does not exist.
How does MOTS-c interact with other medications?
Interaction behaviour in people is not characterised for this substance, which is itself a reason a physician reviews the full medication list before any discussion. Interactions with diabetes medications or other metabolic therapies have not been studied.
What would a physician monitor if MOTS-c were discussed?
Monitoring concepts include Baseline and follow-up metabolic labs, such as fasting glucose markers, are a general concept in any physician-guided discussion; Routine clinical evaluation for unexpected symptoms is a standard component of oversight for any investigational substance; Because no established monitoring protocol exists for MOTS-c specifically, any approach would be individualized and conservative. These are concepts a clinician would apply, not instructions for self-directed use.
How would a GOAL.MD physician evaluate a question about MOTS-c?
A physician starts with the problem you are trying to solve, reviews your history and current medications, and says plainly where the evidence stands. Medical appropriateness is determined only after a full evaluation, and for many substances the honest answer is that the evidence does not support use.
What should I ask a physician about MOTS-c?
Useful questions include: What does the absence of human trial data mean for assessing safety in my specific case?; Are there approved, evidence-based options that address the metabolic goal I'm asking about?; How would you monitor for adverse effects if this were ever discussed as part of a research context?; What is known about how MOTS-c might interact with medications I currently take?.
Why do people ask about MOTS-c?
Patients encounter MOTS-c through longevity and biohacking communities that cite its mitochondrial origin as evidence it might influence metabolic aging, exercise capacity, or insulin sensitivity. The framing often gets ahead of the underlying science, which is still confined to laboratory models.
Who reviews what GOAL.MD publishes about MOTS-c?
Clinical content is reviewed by a named physician for medical accuracy and by a second physician for regulatory and compliance language before it is published, and a review byline appears only when that review is recorded. New material stays unpublished until both reviews are on record.
This page is educational. Nothing here can be ordered, and nothing here is a prescription or medical advice. Compounded preparations are not FDA-approved. To ask about current availability, visit goal.md/peptides/connect or call or text 314-907-3103.
Medically reviewed by Michael Fitch, MD, MD. Last reviewed 2026-08-13.